Skip to main content
. 2021 Nov 17;12(1):90–107. doi: 10.1158/2159-8290.CD-21-0030

Table 1.

Clinical characteristics of patients enrolled in the NCT03340935 trial

Patient population
N = 101
Characteristics N %
Age (years) ≥60 28 27.7
< 60 73 72.3
Sex Male 28 27.7
Female 73 72.3
ECOG PS 0 63 62.4
1 38 37.6
Tumor type Breast

  • Luminal

  • TNBC

  • HER2+

 56

  • 26

  • 19

  • 11

 55.4

  • 46.4

  • 33.9

  • 19.7
Colorectal

  • KRAS mutated

  • BRAF mutated

 10

  • 4

  • 5

 9.9

  • 40

  • 50
Lung 7 6.9
Prostate 4 3.9
Pancreas 3 3
Melanoma 3 3
Germinal 3 3
Ovary 2 2
Thyroid 2 2
Chronic lymphocytic leukemia 2 2
Non-Hodgkin lymphoma 2 2
Uterus 1 1
Sarcoma 1 1
Multiple myeloma 1 1
Stomach 1 1
Kidney 1 1
Mesothelioma 1 1
Myelofibrosis 1 1
Disease stage Advanced 75 74.3
Localized 26 25.7
Concomitant treatment Chemotherapy 73 72.3
Endocrine (± targeted therapies) 13 12.9
Immunotherapy 3 2.9
Targeted therapy 2 2
Radiotherapy 1 1
Radionuclide treatment 1 1
Best supportive care 8 7.9
BMI at enrollment 20–24.9 kg/m2 53 52.5
25–29.9 kg/m2 32 31.7
30–34.9 kg/m2 14 13.9
>35 kg/m2 2 1.9